What is the official website of IPPC Pharmacy ?

The official website of IPPC Pharmacy is http://www.ippcrx.com.

What is IPPC Pharmacy's cybersecurity risk score?

IPPC Pharmacy has an AI-generated cybersecurity risk score of 639 out of 1000, indicating a Poor security posture according to Rankiteo's assessment.

How many security incidents has IPPC Pharmacy experienced?

According to Rankiteo, IPPC Pharmacy currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has IPPC Pharmacy been affected by any supply chain cyber incidents ?

According to Rankiteo, IPPC Pharmacy has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does IPPC Pharmacy have SOC 2 Type 1 certification ?

According to Rankiteo, IPPC Pharmacy is not certified under SOC 2 Type 1.

Does IPPC Pharmacy have SOC 2 Type 2 certification ?

According to Rankiteo, IPPC Pharmacy does not hold a SOC 2 Type 2 certification.

Does IPPC Pharmacy comply with GDPR ?

According to Rankiteo, IPPC Pharmacy is not listed as GDPR compliant.

Does IPPC Pharmacy have PCI DSS certification ?

According to Rankiteo, IPPC Pharmacy does not currently maintain PCI DSS compliance.

Does IPPC Pharmacy comply with HIPAA ?

According to Rankiteo, IPPC Pharmacy is not compliant with HIPAA regulations.

Does IPPC Pharmacy have ISO 27001 certification ?

According to Rankiteo,IPPC Pharmacy is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does IPPC Pharmacy operate in ?

IPPC Pharmacy operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does IPPC Pharmacy have ?

IPPC Pharmacy employs approximately 93 people worldwide.

Does IPPC Pharmacy own any subsidiaries ?

IPPC Pharmacy presently has no subsidiaries across any sectors.

How many LinkedIn followers does IPPC Pharmacy have ?

IPPC Pharmacy's official LinkedIn profile has approximately 274 followers.

What is the NAICS classification code for IPPC Pharmacy ?

IPPC Pharmacy is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does IPPC Pharmacy have a Crunchbase profile ?

No, IPPC Pharmacy does not have a profile on Crunchbase.

Does IPPC Pharmacy have a LinkedIn profile ?

Yes, IPPC Pharmacy maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/ippc-pharmacy.

How many cybersecurity incidents has IPPC Pharmacy experienced ?

As of July 15, 2026, Rankiteo reports that IPPC Pharmacy has experienced 2 cybersecurity incidents.

How many peer or competitor companies does IPPC Pharmacy have ?

IPPC Pharmacy has an estimated 5,708 peer or competitor companies worldwide.

What types of cybersecurity incidents has IPPC Pharmacy faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

IPPC Pharmacy

Boost Score +25 with badge (5 left)

639

/1000

Poor

664

/1000

Weak

IPPC Pharmacy Vendor Cyber Rating & Cyber Score

ippcrx.com

Add Your Compliance Badge

IPPC is a privately owned and operated state of the art long term care pharmacy servicing NJ, PA, and DE. We cater to meet the pharmaceutical needs of skilled nursing, assisted living, personal care, residential health care, and developmentally disabled communities. IPPC provides the most advanced technology to every community we service resulting in a more efficient and cost effective medication management program. We are your pharmacy solution.

IPPC Pharmacy A.I CyberSecurity Scoring

Scoring History

IPPC Pharmacy

IPPC Pharmacy CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

IPPC Pharmacy

Breach

100

9/2025

IPP1775154672

IPPC Pharmacy

Breach

100

9/2025

IPP1775255248

Loading…

A.I.

IPPC Pharmacy Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for IPPC Pharmacy

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for IPPC Pharmacy in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for IPPC Pharmacy in 2026.

Incident Types IPPC Pharmacy vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for IPPC Pharmacy in 2026.

Incident History - IPPC Pharmacy (X = Date, Y = Severity)

Loading…

SUBSIDIARY

IPPC Pharmacy Subsidiaries

Parent Company

IPPC Pharmacy

Pharmaceutical Manufacturing

Website: http://www.ippcrx.com

Company Size: 51-200 employees

No subsidiary data available for this company.

Loading…

IPPC Pharmacy Similar Companies

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Novo Nordisk

novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Fresenius Kabi

fresenius-kabi.com

As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint

Loading…

NEWS

IPPC Pharmacy CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

June 03, 2023 07:00 AM

How these Indigenous pharmacists are building trust and confronting health care's legacy of systemic racism

Efforts are underway to build communities, resources for pharmacists and patients. A man wearing a suit smiles for the camera towards the...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-5270

SUMMARY

An authentication bypass vulnerability exists in certain releases of Ciena Navigator Network Control Suite (NCS), Manage Control Plan (MCP), and Blue Planet products. The issue is caused by improper handling of HTTP request paths and headers, which allows an unauthenticated attacker to manipulate requests in a manner that bypasses authentication and associated audit logging controls.

Published

Date2026-07-14

Updated

Date2026-07-14

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

https://www.ciena.com/product-security

CVE-2026-5269

SUMMARY

In Ciena's Navigator Network Control Suite (NCS) and Manage Control Plan (MCP), there are hidden system accounts used for internal software operations. Some of these accounts have default passwords that may be predictable. While these accounts have very limited permissions on their own, an attacker could combine an attack using one of these accounts with other potential weaknesses to launch a more significant attack, possibly leading to escalation of privilege on the system.

Published

Date2026-07-14

Updated

Date2026-07-14

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

https://www.ciena.com/product-security

CVE-2026-51808

SUMMARY

Buffer Overflow vulnerability in OpenHTJ2K v.0.18.4 and before allows an attacker to execute arbitrary code via the openhtj2k_decoder_impl::invoke, invoke_line_based, invoke_line_based_stream, and invoke_line_based_predecoded function in source/core/interface/decoder.cpp

Published

Date2026-07-14

Updated

Date2026-07-14

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-51807

SUMMARY

Buffer Overflow vulnerability in OpenHTJ2K v.0.18.4 and before allows an attacker to execute arbitrary code via the j2k_precinct_subband::parse_packet_header() in source/core/coding/coding_units.cpp

Published

Date2026-07-14

Updated

Date2026-07-14

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-36035

SUMMARY

Incorrect access control in the /api/License/deactivateOffline endpoint of CAXPerts UniversalPlantViewer WebServices Server v2.7.6 allows authenticated attackers with low-level privileges to cause a Denial of Service (DoS) via removing the license from the webserver.

Published

Date2026-07-14

Updated

Date2026-07-14

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…